And really, it lays out very, very clearly the benefits of looking at bloodstream infections in a holistic manner from sample collection all the way through to rapid susceptibility testing on Pheno. This is something that — if it’s not yet, will be available on BD’s website. It will be showcased at ECCMID next month in Copenhagen, Denmark. It will be part of their overall pitch and strategy at the ECCMID Conference, which is the largest global microbiology conference in the world that will be showcased there. And clearly, Pheno will be there and Arc will be there as well, which is a big, big part of this bloodstream infection strategy for BD. Dustin, did we answer all your questions? Do you have any follow-up questions?
Dustin Scaringe: No. You answered all of them. That was great. And that’s it for us. Thanks for taking the questions.
Jack Phillips: Great. Thank you, Dustin. And Gary, are those all the questions for today?
Operator: Yes, sir. There are no further questions.
Jack Phillips: Okay. Thank you. So in summary, first of all, I want to welcome David Patience to the leadership team of Accelerate as our new CFO here. As you heard today, David’s wasted no time in jumping in. He’s been deep into all aspects of our business from many aspects of finance, but all the way through in the commercial business and then obviously the BD integration. So we’re thrilled to have him on board and thanks, Steve, again for his tremendous contributions over the past decade at Accelerate. I want to remind you of three important strategic priorities as we close out. Very near term is the financial strength and stability of Accelerate. And I just rest assured, I want everyone to know that we’re working day and night to solve our debt overhang issue with the current debt holders.
We expect in short term to have a resolution that we’ll be able to clearly communicate to all shareholders and investors and more to come on that. But rest assured, we are in good faith negotiations currently, and we expect them to continue and lead to a productive and positive outcome. The second thing I would say that I know investors, shareholders are wanting more information on is how are things going with BD? How is this producing market growth opportunities? How is it producing new placements, new deals? Rest assured, that is another item that we are working on hard every day. We are up and running. We’re active in the U.S. We’re coming along in EMEA. And we — again, we expect closes to be more towards the back half of the year, but we will and do expect to provide more detailed metrics and update on our progress.
But overall, going very well and what a great partner that we have in BD, and it’s a true complement. Our solutions are just a total complement for microbiology and susceptibility testing globally. And then the last thing that we’ll continue to update on that is extremely exciting is our next-generation platform Wave as we drive innovation. And also, what I didn’t talk much about today is Arc and really continuing to move Arc forward as we work with the FDA to get Arc on market in the U.S. Wave is an exciting platform that will really change the financial dynamics for Accelerate because of the cost of goods sold. From a market standpoint, it’s going to open up an entirely new segment of the market for us, that high-volume, low acuity market in susceptibility testing that’s focused on isolate samples.
